HCV genotype-3a T cell immunity: Specificity, function and impact of therapy

Gut

Volumn 61, Issue 11, 2012, Pages 1589-1599

  Humphreys, Isla S ^a   Von Delft, Annette ^a   Brown, Anthony ^a   Hibbert, Linda ^b   Collier, Jane D ^c   Foster, Graham R ^b   Rahman, Monira ^a,c   Christian, Annabel ^c   Klenerman, Paul ^a,d   Barnes, Eleanor ^a,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; HLA ANTIGEN; NONSTRUCTURAL PROTEIN 1; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN;

ANTIGEN DETECTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; GENE MAPPING; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 3A; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SPECIES DIVERSITY; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; MALE; REFERENCE VALUES; RIBAVIRIN; SENSITIVITY AND SPECIFICITY; T-CELL ANTIGEN RECEPTOR SPECIFICITY;

EID: 84867017596     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300650     Document Type: Article

References (45)

1. World Health Organisation. Hepatitis Cdglobal prevalence (update). Wkly Epidemiol Rec 1999;74 :4211-428.
2. Lauer GM, Barnes E, Lucas M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004;127:924-36.
3. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 2004; 85:3173-88.
4. Pybus OG, Barnes E, Taggart R, et al. Genetic history of hepatitis C Virus in East Asia. J Virol 2009;83:1071-82.
5. Uddin G, Shoeb D, Solaiman S, et al. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat 2010;17:327-35.
6. Health Protection Agency. Hepatitis C in the UK: Annual Report 2009. London: Health Protection Agency Centre for Infections, 2009.
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347 :975-82.
8. Taylor DR, Shi ST, Romano PR, et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999;285:107-10.
9. Sarrazin C, Kornetzky I, Rüster B, et al. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. Hepatology 2000;31:1360-70.
10. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45. 1345 e1-7.
11. Moghaddam A, Melum E, Reinton N, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011;53:746-54.
12. Diepolder HM. Interferon-[alpha] for hepatitis C: antiviral or immunotherapy? J Hepatol 2004;40:1030-1.
13. Giugliano S, Oezkan F, Bedrejowski M, et al. Degree of cross-genotype reactivity of hepatitis C virus-specific CD8+ T cells directed against NS3. Hepatology 2009;50:707-16.
14. Rauch A, James I, Pfafferott K, et al. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology 2009;50:1017-29.
15. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009;49:1069-82.
16. Humphreys I, Fleming V, Fabris P, et al. Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection. J Virol 2009;83:11456-66.
17. Biodefense and emerging infections Research resources Repository (BEI resources). http://www.beiresources.org/
18. Draenert R, Brander C, Yu XG, et al . Impact of intrapeptide epitope location on CD8 T cell recognition: implications for design of overlapping peptide panels. AIDS 2004;18:871-6.
19. Tamura K, Peterson D, Peterson N, et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011;28:2731-9.
20. Barnes E, Gelderblom HC, Humphreys I, et al. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. J Infect Dis 2009;199:819-28.
21. Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012;4:115ra2.
22. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-512.
23. Fleming VM, Harcourt G, Barnes E, et al. Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection. J Gen Virol 2010;91:1396-406.
24. Semmo N, Day CL, Ward SM, et al. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 2005;41:1019-28.
25. Harcourt G, Gomperts E, Donfield S, et al. Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in human immunodeficiency virus/ hepatitis C virus coinfected patients. Gut 2006;55:1484-7.
26. Semmo N, Krashias G, Willberg C, et al. Analysis of the relationship between cytokine secretion and proliferative capacity in hepatitis C virus infection. J Viral Hepat 2007;14:492-502.
27. Semmo N, Barnes E, Taylor C, et al. T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet 2005;365:327-9.
28. Andri R, Ian J, Katja P, et al. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology 2009;50:1017-29.
29. Godkin A, Jeanguet N, Thursz M, et al. Characterization of novel HLA-DR11- restricted HCV epitopes reveals both qualitative and quantitative differences in HCVspecific CD4+ T cell responses in chronically infected and non-viremic patients. Eur J Immunol 2001;31:1438-46.
30. Barnes E, Harcourt G, Brown D, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002; 36:743-54.
31. Day CL, Lauer GM, Robbins GK, et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol 2002; 76:12584-95.
32. Pilli M, Zerbini A, Penna A, et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV Project). Gastroenterology 2007; 133 :1132-43.
33. Health Protection Agency Centre for Infections. Hepatitis C in the UK 2008. London: HPA, 2008.
34. Ruys TA, Nanlohy NM, van den Berg CH, et al. HCV-specific T-cell responses in injecting drug users: evidence for previous exposure to HCV and a role for CD4+ T cells focussing on nonstructural proteins in viral clearance. J Viral Hepat 2008;15:409-20.
35. Fuller MJ, Shoukry NH, Gushima T, et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 2010;51:378-87.
36. Neumann-Haefelin C, Timm J, Spangenberg HC, et al. Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology 2008;47:1824-36.
37. Wong DK, Dudley DD, Afdhal NH, et al. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 1998; 160:1479-88.
38. Lamonaca V, Missale G, Urbani S, et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 1999;30:1088-98.
39. Schulze zur Wiesch J, Lauer GM, Day CL, et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 2005;175:3603-13.
40. Hultgren C, Desombere I, Leroux-Roels G, et al. Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol 2004; 40:971-8.
41. Cramp ME, Rossol S, Chokshi S, et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118 :346-55.
42. Kamal SM, Fehr J, Roesler B, et al. Peginterferon alone or with ribavirin enhances HCV-specific CD4+ T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002;123:1070-83.
43. Rosen HR, Weston SJ, Im K, et al . Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 2007; 46:350-8.
44. Burton JR Jr, Klarquist J, Im K, et al. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol 2008;49:329-38.
45. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105 :7034-9.